BioNTech and Fosun Pharma Initiate Clinical Trial of BNT162b1 Against COVID-19 in China
Shots: The P-I study will evaluate the safety and immunogenicity of the vaccine as well as confirm dose selection in ~144 healthy subjects aged 18-55 and >55 yrs. As part of the two-dose cohort design, subjects will receive two injections (prime-boost), 21 days apart BNT162b1 vs PBO The dose range was determined based on early […]